In recent years, some policymakers have suggested the United States is too dependent on imports of certain products from countries like China. With the outbreak of COVID-19, the calls to reshore the supply chain of a number of products, including pharmaceuticals and other medical equipment, have intensified.

Policymakers hoping to usher in a new era of industrial policy should be cautious. Reshoring the entire pharmaceutical supply chain would increase costs for consumers, dampen innovation and hurt the competitiveness of a global industry.

In conjunction with the release of a new R Street white paper exploring all of the major issues surrounding the pharmaceutical supply chain, we invite you to a webinar that will dispel a number of myths and offer positive, concrete ideas that are available to policymakers.


Clark Packard (Moderator)

Resident Fellow and Trade Policy Counsel, R Street Institute

Bill Watson

Associate Fellow, R Street Institute

Jacqueline Varas

Director of Immigration and Trade Policy, American Action Forum

Eric Boehm 

Reporter, Reason